Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Sue Simpson and Armando Burls.
A West Midlands Develop-ment and Evaluation Service Report.
A Systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection,
[2.]
X. Carbonell-Estrany, J. Quero.
Comité de Estándares de la Sociedad Española de Neonatología Recomendaciones para la prevención de la infección por virus respiratorio sincitial.
An Esp Pediatr, 52 (2000), pp. 372-374
[3.]
X. Carbonell-Estrany.
J Quero J y Comité de Estándares de la Sociedad Española de Neonatología Recomendaciones para la prevención de la infección por Virus Respiratorio Sincitial: revi-sión.
An Esp Pediatr, 56 (2002), pp. 334-336
[4.]
American Academy of Pediatrics.
Prevention of Respiratory Syncytial Virus infections: Indications for the use of Palivizu-mab and update on the use of RSV-IGIV.
Pediatrics, 5 (1998), pp. 1211-1215
[5.]
The impact-rsv study group.
Palivizumab a humanized respiratory syncytial virus monoclonal antibody, reduces hos-pitalization from respiratory syncytial virus infection in high –risk infants.
Pediatrics, 102 (1998), pp. 531-537
[6.]
American Academy of Pediatrics.
Report of the Committee on Infectious Disease Respiratory syncytial virus.
Red Book, 26th ed, pp. 523-528
[7.]
X. Carbonell-Estrany, J. Quero, G. Bustos, A. Cotero, E. Doménech, J. Figueras-Aloy, et al.
Rehospitalization because of respira-tory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study: IRIS Study Group.
Pediatr Infect Dis J, 19 (2000), pp. 592-597
[8.]
X. Carbonell-Estrany, J. Quero.
and IRIS Study Group: RSV hos-pitalization rates in premature infants born over two consecu-tive season.
Pediatr Infect Dis J, 20 (2001), pp. 874-879
[9.]
C. Pedraz, X. Carbonell-Estrany, J. Figueras-Aloy.
Quero J and the IRIS Study Group.
Effect of Palivizumab prophilaxis in decrea-sing respiratory syncitial virus hospitalitations in premature infants Pediatr Infect Dis J, 22 (2003), pp. 823-827
[10.]
T.J. Moore, S.R. Weis, S. Kaplan, C.J. Blaisdell.
Reported adverse drugs events in infants and children under 2 years of age.
Pediatrics, 110 (2002), pp. 1-5
[11.]
Moore TJ, Weis SR, Blaisdell CR. Reported fatal and serious adverse reactions associated with palivizumab. (abstract) Pediatr Acad Soc 2002. Available at: http://www.pas-mee-ting.org/2002baltimore
[12.]
S. Lapeña López de Armentía, M.a B. Robles García, J.P. Martínez Badás, L. Castañón Fernández, J. Mallo Castaño, B. Herrero Mendoza, et al.
Impacto potencial y análisis coste-eficacia de la profilaxis con palivizumab, en la prevención de bronquiolitis, en prematuros menores de 33 semanas de gestación.
An Pediatr (Barc), 59 (2003), pp. 328-333
[13.]
I. Danés Carreras, J.M. Arnau de Bolos.
Profilaxis de las infeccio-nes por virus respiratorio sincitial con palivizumab.
An Esp Pediatr, 56 (2002), pp. 289-291
[14.]
S. Joffe, G.T. Ray, G.J. Escobar, S.B. Black, T.A. Lien.
Cost-efectiveness of respiratory syncytial virus prophilaxis among preterm infants.
Pediatrcs, 104 (1999), pp. 419-427
[15.]
S. Joffe, G.T. Ray, G.J. Escobar, S.B. Black, T.A. Lieu.
Rehospitalization for respiratory syncytial virus among preterm infants.
Pediatrcs, 104 (1999), pp. 894-899
[16.]
W. Frank, F.W. Moler.
RSV Immune Globulin Prophylaxis: Is an ounce of prevention worth a pound of cure?.
Pediatrcs, 104 (1999), pp. 559
Copyright © 2004. Asociación Española de Pediatría
